Holly L. Pacenta

Hematology | Oncology
1500 Cooper St
Fort Worth, TX 76104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances
Published: March 24, 2026

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Journal: Blood neoplasia
Published: March 03, 2026

Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.

Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.

Journal: Leukemia
Published: December 31, 2025

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances
Published: April 29, 2025

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Journal: Blood advances
Published: April 14, 2025

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Journal: Blood
Published: September 09, 2024

Risk of transfusion-related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center.

Risk of transfusion-related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center.

Journal: Pediatric blood & cancer
Published: May 10, 2024

Mediport use as an acceptable standard for CAR T cell infusion.

Mediport use as an acceptable standard for CAR T cell infusion.

Journal: Frontiers in immunology
Published: June 12, 2023

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.

Journal: EClinicalMedicine
Published: March 13, 2023

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 15, 2022

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.

Journal: Blood advances
Published: September 07, 2022

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.

Journal: Blood advances
Published: February 04, 2022
Showing 1-12 of 21

Last Updated: 09/26/2026